Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD responds to Solensia injection concerns
Solensia is used to alleviate osteoarthritis pain in cats.
Anaphylaxis has been added to the SPC as an adverse event.

The VMD has added anaphylaxis to the SPC of Solensia 7 mg/ml Solution for Injection for Cats.

It says that this is a rare side effect, with such adverse events affecting fewer than three animals for every 1000 doses of Solensia sold.

Solensia is used to alleviate osteoarthritis pain in cats. It contains the active ingredient frunevetmab.

Anaphylaxis joins effects such as alopecia, dermatitis, pruritus on the list of adverse effects.

The VMD says that is constantly reviewing adverse event data for all medicines.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'